ZOVIRAX RESISTANCE NOT CLINICALLY SIGNIFICANT, BURROUGHS WELLCOME
This article was originally published in The Tan Sheet
Executive Summary
ZOVIRAX RESISTANCE NOT CLINICALLY SIGNIFICANT, BURROUGHS WELLCOME research scientist Jack Hill suggested at a May 19 FDA public hearing on the company's Rx-to-OTC switch application for Zovirax (acyclovir). "We believe that acyclovir-resistant viruses ...cause little if any clinically significant diseases in people with healthy immune systems," Hill said.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning